Ann: Positive in vitro data for CHM 1301 CAR NK cells, page-68

First 68 Last

Share
Profile

Follow
slick

16,087 Posts.

8968

23/11/23

21:24

Post #: 71078542
Share

Originally posted by Steini: ↑

Rythex, you know that's the problem with charts.

"... This ugly top left bottom right looking chart - With over 80% of the shareholder value wiped since listing..." is as accurate as the past and failed 3 times to predict a 30-40% spike in the past few weeks.

If you just invest based on charts alone you either never or always buy or will always sit on the sidelines watching as on any given day the chart predicts either up, staying the same or down.

Today's anns was never meant to be a game changer, more a confirmation that CHM's next gen CAR-T 1101, now called CHM1301 can be used to treat other SOLID cancers too. The big announcements recently were the CHM 1101 GMB Ph1 read out and the CDH 17 IND. 2 years ago those would have taken the sp to $1. These days any non-income tech stock is valued at ZERO regardless of asset-development and cash at hand.

Regardless of how many shares will be issued and cash received the EV would be less than $ 10m if the sp stays at the 3c level. But as soon as CHM turns the current "quick" Ph1b into a pivotal / registrational trial - already foreshadowed by the FDA - the big guys will notice and trying to get their hands on it. At this stage nobody can beat CHM when it comes to GBM treatments and that alone is worth more than just AUD 10m.

Did I mention that CHM and IMU are the only ASX listed companies having clinical trials underway using different types of CAR-T. And do you know that CHM's CEO has been among the few scientists in the world who participated developing CD 19 - CAR-Ts?

Not sure if the charts can tell you that.

GLTA

Expand

Totally agree with this. I’ve tried and failed twice here. That’s not a negative to the company, it’s just the way it trades and how important liquidity is in successful charting. IMO.

Cheers all, sincerely hope this one works out.

CHM Price at posting: 3.1¢ Sentiment: None Disclosure: Not Held
7 Upvote

1 Great analysis

Reply

Top Stories

IXR

Ionic Rare Earths falls -7% as momentum slips on vague production update

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

NUZ

Neurizon inks $1.5M loan against R&D Tax Rebate

HAR

Haranga jumps +7% on Lincoln acquisition

ASX Market Close: Index rebounds as investors buoyant | July 30, 2025

First 68 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.4¢		Change 0.001(33.3%)		Mkt cap ! $12.99M

Open	High	Low	Value	Volume
0.3¢	0.4¢	0.3¢	$949	312.2K

Buyers (Bids)

No.	Vol.	Price($)
70	67782438	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	91927011	27

View Market Depth

No.	Vol.	Price($)
70	67782438	0.003
26	26746044	0.002
13	54414000	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	91927011	27
0.005	33248062	21
0.006	17929018	21
0.007	6512518	7
0.008	7317101	5

Last trade - 16.10pm 30/07/2025 (20 minute delay)

CHM (ASX) Chart

Ann: Positive in vitro data for CHM 1301 CAR NK cells, page-68

Ionic Rare Earths falls -7% as momentum slips on vague production update

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

Neurizon inks $1.5M loan against R&D Tax Rebate

Haranga jumps +7% on Lincoln acquisition

ASX Market Close: Index rebounds as investors buoyant | July 30, 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Positive in vitro data for CHM 1301 CAR NK cells, page-68

Top Stories

Ionic Rare Earths falls -7% as momentum slips on vague production update

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

Neurizon inks $1.5M loan against R&D Tax Rebate

Haranga jumps +7% on Lincoln acquisition

ASX Market Close: Index rebounds as investors buoyant | July 30, 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News